Multiple sclerosis

  title={Multiple sclerosis},
  author={Ernst U. Walther and Reinhard Hohlfeld},
  pages={1622 - 1622}
Article abstract Interferon beta (IFNβ) reduces the relapse rate, disease activity as measured by serial MRI scanning, and disease progression of MS. Therapy with IFNβ may be associated with a number of adverse reactions. Relatively frequent side effects include flu-like symptoms, transient laboratory abnormalities, menstrual disorders, and increased spasticity. Dermal injection site reactions occur after subcutaneous application of IFNβ-1b and IFNβ-1a. Possible side effects of IFNβ include… 

Tables from this paper

Arthritis during interferon beta-1b treatment in multiple sclerosis
Clinical and laboratory findings of two MS patients who developed arthritis during IFN-β1b treatment, probably of autoimmune origin are presented.
Interferon-beta injection site reactions in patients with multiple sclerosis
Injection site reactions (ISRs), featured by erythema, edema, pain, and pruritus, are the most common adverse reactions and it is very important to adopt strategies to minimize ISRs by proper patient education and counseling.
The safety and efficacy of IFN-β products for the treatment of multiple sclerosis
Overall, IFN-β is safe and generally well tolerated, and reported adverse events were comparable between preparations, and systemic side effects can be effectively managed by dose escalation, use of an auto-injector and careful clinical monitoring.
Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis
There is growing evidence from clinical trials on relapsing-remitting MS and clinically isolated syndromes suggestive of MS that IFNβ-1b reduces the frequency and severity of relapses and the development of new and active brain lesions as assessed by magnetic resonance imaging.
Cutaneous Adverse Events Associated with Interferon-β Treatment of Multiple Sclerosis
A multiple sclerosis patient treated with interferon-β who developed new-onset psoriasis is presented and it is suggested that skin lesions may serve as biomarkers to allocate MS patients to adequate disease-modifying drugs.
Managing Risks with Immune Therapies in Multiple Sclerosis
This paper aims to provide an overview of currently available MS therapies, their modes of action and safety profiles, and the necessary therapy monitoring.
Thrombotic microangiopathy associated with use of interferon-beta
A patient who developed thrombotic microangiopathy during treatment with interferon-beta and improved after discontinuation and steroid therapy is reported.
Current Clinical Applications of Interferon
Flu-like symptoms, fever, headache, fatigue and myalgia are experienced by three quarters of patients, but this reaction can usually be managed with NSAIDs and resolved within the first three months after initiation of IFN--1b treatment.
Interferons in multiple sclerosis.
  • L. Kappos
  • Medicine, Biology
    Neurologic clinics
  • 2005
Recurrent nephrotic syndrome in patient with multiple sclerosis treated with interferon beta-1a
A patient with multiple sclerosis treated with interferon (IFN) β–1a who developed a recurrent nephrotic syndrome several months after the beginning of therapy may support an immune-mediated mechanism underlying the glomerular damage.


Side effect profile of interferon beta-lb in MS
If future clinical trials are to provide useful information on the value of interferon beta-1b in progressive MS, the side effects of fatigue and depression will need to be ameliorated to limit the drop-out rate from such trials.
Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b.
Since some symptoms of thyroid dysfunction may be difficult to distinguish from typical MS-related symptoms, thyroid hormone levels should be checked when unexplained constitutional symptoms occur during IFN-beta-1b therapy.
Management of patients receiving interferon beta-1b for multiple sclerosis
Article abstract-Results of a double-blind, placebo-controlled study in ambulatory patients with relapsing-remitting MS showed that interferon beta-1b reduced the rate of exacerbations by one-third
Autoimmune events during interferon beta-1b treatment for multiple sclerosis
No eidence for increased frequency of autoantibodies during interferon‐βlb treatment of multiple sclerosis
Although examined on a rather small group of patients, the results show no evidence of increased frequency of autoantibodies during interferon‐βlb treatment of multiple sclerosis.
Clinical Toxicity of the Interferons
The mechanisms underlying toxic effects of the interferons are not well understood, and the incidence of adverse effects is usually dose- and duration-dependent.
Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b
The annual exacerbation rates in NAB-negative patients receiving the 8-MIU dosage regimen are about 50% of those seen in untreated patients, a greater reduction than the one-third reduction earlier reported for the entire high-dose arm, and a meaningful treatment benefit.
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Interferon beta‐ la had a significant beneficial impact in relapsing multiple sclerosis patients by reducing the accumulation of permanent physical disability, exacerbation frequency, and disease activity measured by gadolinium‐enhanced lesions on brain magnetic resonance images.
Ibuprofen treatment versus gradual introduction of interferon β-1b in patients with MS
The combination of ibuprofen and interferon β-1b reduced the incidence of flu-like symptoms to rates comparable with the placebo group in the pivotal trial but increased the frequency of injection site reactions, albeit modestly and transiently.